Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.
Lead Product(s): CAR T-Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Generate Biomedicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2023
Details:
Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalone efficacy in a number of solid tumors.
Lead Product(s): Rintatolimod,Interferon Alfa-2B,Paclitaxel
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Aim ImmunoTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
Lead Product(s): Rintatolimod,Interferon Alfa-2B,Celecoxib
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Aim ImmunoTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
The data, from a small number of subjects, is extremely impressive for four out of six Ampligen plus pembrolizumab patients; three demonstrated disease stabilization and one showed a significant and dramatic rapid destruction of the tumor and metastasis.
Lead Product(s): Rintatolimod,Celecoxib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Aim ImmunoTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
Primary endpoint of the study was met for Ampligen (rintatolimod), selective TLR3 ligand, evidenced by increased CD8a expression post-treatment (p=0.046), as a component of treatment for colorectal cancer metastatic to the liver.
Lead Product(s): Rintatolimod,Celecoxib,Recombinant Interferon Alfa-2b
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Aim ImmunoTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022